株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

視神経脊髄炎関連疾患(NMOSD)- 疫学予測 ~2027年

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027

発行 DelveInsight Business Research LLP 商品コード 736667
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
視神経脊髄炎関連疾患(NMOSD)- 疫学予測 ~2027年 Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027
出版日: 2018年10月01日 ページ情報: 英文 60 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における視神経脊髄炎関連疾患(NMOSD)の有病数は2016年に3万2,382人と推計されています。

当レポートでは、視神経脊髄炎関連疾患(NMOSD)市場について調査し、疾患の概要、患者背景、主要7カ国における有病数・診断数の予測(今後10年間分)、診断ガイドライン、市場規模、市場の成長要因・障壁、競合情勢などを包括的にまとめています。

目次

第1章 重要な洞察

第2章 視神経脊髄炎関連疾患(NMOSD):市場概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 視神経脊髄炎関連疾患(NMOSD):疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • 視神経脊髄炎/関連疾患(NMO/NMOSD)の臨床症状
  • 分類
  • 病因
  • 診断
  • 診断基準
  • 神経イメージング・神経生理学的検査

第4章 疫学と患者人口

  • 主な所見

第5章 主要7カ国における視神経脊髄炎関連疾患(NMOSD)の有病数

第6章 主要7カ国における視神経脊髄炎関連疾患(NMOSD)の疫学:国別

  • 米国
    • 前提と根拠
    • 総有病数
    • 有病数:性別
    • 総診断数
    • 診断数:NMO-IgG
    • 臨床症状
    • 有害事象
  • 主要欧州5カ国
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
  • 日本

第7章 市場の成長要因

第8章 市場の障壁

第9章 付録

  • 調査方法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Signs and Symptoms of Neuromyelitis Optica
  • Table 2: Brain symptoms in Neuromyelitis Optica
  • Table 3: NMOSD diagnostic criteria for adult patients
  • Table 4: Red flags: Findings atypical for NMOSD
  • Table 5: Neuroimaging characteristics of NMOSD
  • Table 6: Total Prevalent Population of NMO/NMOSD in the 7MM (2016-2027)
  • Table 7: Total Prevalent Population of NMO/NMOSD in the US (2016-2027)
  • Table 8: Gender Specific Prevalence of NMO/NMOSD in the US (2016-2027)
  • Table 9: Diagnosed Cases of Neuromyelitis Optica in the US (2016-2027)
  • Table 10: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Table 11: Clinical Characterization of NMO/NMOSD in the US (2016-2027)
  • Table 12: Events of NMO/NMOSD in the US (2016-2027)
  • Table 13: Total Prevalent Population of NMO/NMOSD in Germany (2016-2027)
  • Table 14: Gender Specific Prevalence of NMO/NMOSD in Germany (2016-2027)
  • Table 15: Diagnosed Cases of Neuromyelitis Optica in Germany (2016-2027)
  • Table 16: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Table 17: Clinical Characterization of NMO/NMOSD in Germany (2016-2027)
  • Table 18: Events of NMO/NMOSD in Germany (2016-2027)
  • Table 19: Total Prevalent Population of NMO/NMOSD in France (2016-2027)
  • Table 20: Gender Specific Prevalence of NMO/NMOSD in France (2016-2027)
  • Table 21: Diagnosed Cases of Neuromyelitis Optica in France (2016-2027)
  • Table 22: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Table 23: Clinical Characterization of NMO/NMOSD in France (2016-2027)
  • Table 24: Events of NMO/NMOSD in France (2016-2027)
  • Table 25: Total Prevalent Population of NMO/NMOSD in Italy (2016-2027)
  • Table 26: Gender Specific Prevalence of NMO/NMOSD in Italy (2016-2027)
  • Table 27: Diagnosed Cases of Neuromyelitis Optica in Italy (2016-2027)
  • Table 28: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Table 29: Clinical Characterization of NMO/NMOSD in Italy (2016-2027)
  • Table 30: Events of NMO/NMOSD in Italy (2016-2027)
  • Table 31: Total Prevalent Population of NMO/NMOSD in The UK (2016-2027)
  • Table 32: Gender Specific Prevalence of NMO/NMOSD in The UK (2016-2027)
  • Table 33: Diagnosed Cases of Neuromyelitis Optica in The UK (2016-2027)
  • Table 34: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2016-2027)
  • Table 35: Clinical Characterization of NMO/NMOSD in The UK (2016-2027)
  • Table 36: Events of NMO/NMOSD in The UK (2016-2027)
  • Table 37: Total Prevalent Population of NMO/NMOSD in Spain (2016-2027)
  • Table 38: Gender Specific Prevalence of NMO/NMOSD in Spain (2016-2027)
  • Table 39: Diagnosed Cases of Neuromyelitis Optica in Spain (2016-2027)
  • Table 40: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Table 41: Clinical Characterization of NMO/NMOSD in Spain (2016-2027)
  • Table 42: Events of NMO/NMOSD in Spain (2016-2027)
  • Table 43: Total Prevalent Population of NMO/NMOSD in Japan (2016-2027)
  • Table 44: Gender Specific Prevalence of NMO/NMOSD in Japan (2016-2027)
  • Table 45: Diagnosed Cases of Neuromyelitis Optica in Japan (2016-2027)
  • Table 46: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Table 47: Clinical Characterization of NMO/NMOSD in Japan (2016-2027)
  • Table 48: Events of NMO/NMOSD in Japan (2016-2027)

List of Figures

  • Figure 1: Signs and symptoms of NMO/NMOSD
  • Figure 2: Clinical features of NMO/NMOSD
  • Figure 3: Neuromyelitis Optica Pathogenesis
  • Figure 4: Total Prevalent Patient Population of NMO/NMOSD in the 7MM (2016-2027)
  • Figure 5: Total Prevalent Population of NMO/NMOSD in the US (2016-2027)
  • Figure 6: Gender Specific Prevalence of NMO/NMOSD in the US (2016-2027)
  • Figure 7: Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Figure 8: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2016-2027)
  • Figure 9: Clinical Characterization of NMO/NMOSD in the US (2016-2027)
  • Figure 10: Events of NMO/NMOSD in the US (2016-2027)
  • Figure 11: Total Prevalent Population of NMO/NMOSD in Germany (2016-2027)
  • Figure 12: Gender Specific Prevalence of NMO/NMOSD in Germany (2016-2027)
  • Figure 13: Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Figure 14: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2016-2027)
  • Figure 15: Clinical Characterization of NMO/NMOSD in Germany (2016-2027)
  • Figure 16: Events of NMO/NMOSD in Germany (2016-2027)
  • Figure 17: Total Prevalent Population of NMO/NMOSD in France (2016-2027)
  • Figure 18: Gender Specific Prevalence of NMO/NMOSD in France (2016-2027)
  • Figure 19: Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Figure 20: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2016-2027)
  • Figure 21: Clinical Characterization of NMO/NMOSD in France (2016-2027)
  • Figure 22: Events of NMO/NMOSD in France (2016-2027)
  • Figure 23: Total Prevalent Population of NMO/NMOSD in Italy (2016-2027)
  • Figure 24: Gender Specific Prevalence of NMO/NMOSD in Italy (2016-2027)
  • Figure 25: Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Figure 26: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2016-2027)
  • Figure 27: Clinical Characterization of NMO/NMOSD in Italy (2016-2027)
  • Figure 28: Events of NMO/NMOSD in Italy (2016-2027)
  • Figure 29: Total Prevalent Population of NMO/NMOSD in The UK (2016-2027)
  • Figure 30: Gender Specific Prevalence of NMO/NMOSD in The UK (2016-2027)
  • Figure 31: Diagnosed Cases of NMO/NMOSD in The UK (2016-2027)
  • Figure 32: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2016-2027)
  • Figure 33: Clinical Characterization of NMO/NMOSD in The UK (2016-2027)
  • Figure 34: Events of NMO/NMOSD in The UK (2016-2027)
  • Figure 35: Total Prevalent Population of NMO/NMOSD in Spain (2016-2027)
  • Figure 36: Gender Specific Prevalence of NMO/NMOSD in Spain (2016-2027)
  • Figure 37: Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Figure 38: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2016-2027)
  • Figure 39: Clinical Characterization of NMO/NMOSD in Spain (2016-2027)
  • Figure 40: Events of NMO/NMOSD in Spain (2016-2027)
  • Figure 41: Total Prevalent Population of NMO/NMOSD in Japan (2016-2027)
  • Figure 42: Gender Specific Prevalence of NMO/NMOSD in Japan (2016-2027)
  • Figure 43: Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Figure 44: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2016-2027)
  • Figure 45: Clinical Characterization of NMO/NMOSD in Japan (2016-2027)
  • Figure 46: Events of NMO/NMOSD in Japan (2016-2027)
目次
Product Code: DIEI0362

DelveInsight's 'Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Disease Understanding and Treatment Algorithm

The DelveInsight Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.

Neuromyelitis Optica Spectrum Disorder Epidemiology

The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

According to DelveInsight, the prevalent cases of NMOSD was 32,382 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of NMOSD with 16,000 prevalent cases in 2016.

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female], NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

Report Scope

  • The report covers detailed overview of Neuromyelitis Optica Spectrum Disorder explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Neuromyelitis Optica Spectrum Disorder
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Neuromyelitis Optica Spectrum Disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuromyelitis Optica Spectrum Disorder Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Neuromyelitis Optica Spectrum Disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Neuromyelitis Optica Spectrum Disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder market.

Table of Contents

1. Key Insights

2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2017
  • 2.2. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2027

3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Clinical features of NMO/NMOSD
  • 3.4. Classification
  • 3.5. Pathogenesis
  • 3.6. Diagnosis
  • 3.7. International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders
  • 3.8. Neuroimaging and neurophysiologic testing
    • 3.8.1. Considerations for AQP4-IgG serologic and another laboratory testing.
    • 3.8.2. Pediatric NMOSD criteria
    • 3.8.3. Monophasic NMOSD
    • 3.8.4. Systemic autoimmunity associated with NMOSD.
    • 3.8.5. Pathology
    • 3.8.6. Opticospinal MS

4. Epidemiology and Patient Population

  • 4.1. Key Findings

5. 7MM Total Prevalent Patient Population of NMO/NMOSD

6. Country Wise-Epidemiology of NMO/NMOSD

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of NMO/NMOSD
    • 6.1.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.1.4. Total Diagnosed Population of NMO/NMOSD
    • 6.1.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.1.6. Clinical Characterization of NMO/NMOSD
    • 6.1.7. Events of NMO/NMOSD
  • 6.2. EU5 Countries
    • 6.2.1. Assumptions and Rationale
  • 6.3. Germany
    • 6.3.1. Total Prevalent Population of NMO/NMOSD
    • 6.3.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.3.3. Total Diagnosed Population of NMO/NMOSD
    • 6.3.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.3.5. Clinical Characterization of NMO/NMOSD
    • 6.3.6. Events of NMO/NMOSD
  • 6.4. France
    • 6.4.1. Total Prevalent Population of NMO/NMOSD
    • 6.4.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.4.3. Total Diagnosed Population of NMO/NMOSD
    • 6.4.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.4.5. Clinical Characterization of NMO/NMOSD
    • 6.4.6. Events of NMO/NMOSD
  • 6.5. Italy
    • 6.5.1. Total Prevalent Population of NMO/NMOSD
    • 6.5.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.5.3. Total Diagnosed Population of NMO/NMOSD
    • 6.5.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.5.5. Clinical Characterization of NMO/NMOSD
    • 6.5.6. Events of NMO/NMOSD
  • 6.6. United Kingdom
    • 6.6.1. Total Prevalent Population of NMO/NMOSD
    • 6.6.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.6.3. Total Diagnosed Population of NMO/NMOSD
    • 6.6.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.6.5. Clinical Characterization of NMO/NMOSD
    • 6.6.6. Events of NMO/NMOSD
  • 6.7. Spain
    • 6.7.1. Total Prevalent Population of NMO/NMOSD
    • 6.7.2. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.7.3. Total Diagnosed Population of NMO/NMOSD
    • 6.7.4. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.7.5. Clinical Characterization of NMO/NMOSD
    • 6.7.6. Events of NMO/NMOSD
  • 6.8. Japan
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Prevalent Population of NMO/NMOSD
    • 6.8.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.8.4. Total Diagnosed Population of NMO/NMOSD
    • 6.8.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.8.6. Clinical Characterization of NMO/NMOSD
    • 6.8.7. Events of NMO/NMOSD

7. Market Drivers

8. Market Barriers

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Back to Top